Gul Ozgur Baris, Somunkiran Asli, Yucel Oguz, Demirci Fuat, Ozdemir Ismail
School of Medicine, Department of Obstetrics and Gynecology, Duzce University, Konuralp, Duzce, Turkey.
Arch Gynecol Obstet. 2008 Jan;277(1):25-30. doi: 10.1007/s00404-007-0401-x. Epub 2007 Jul 6.
Women with polycystic ovary syndrome (PCOS) have multiple risk factors for cardiovascular disease. The cardiovascular risk marker homocysteine (Hcy) is elevated in women with PCOS. This prospective study investigated the effect of oral contraceptives containing ethinyl estradiol-cyproterone acetate (EE-CA) on serum Hcy levels in women with PCOS.
A total of 30 women with PCOS were enrolled in this prospective study. The diagnosis of PCOS was made according to the criteria of the Rotterdam PCOS consensus workshop group. All women took oral contraceptives containing EE/CA (35 microg/2 mg) for 3 months. Serum samples for Hcy, lipid profile and hormones were obtained during the early follicular phase (days 3-5) of the spontaneous or progestin-induced bleeding at baseline, and after the third treatment cycle.
Three months of EE-CA therapy significantly decreased the Hcy levels from 55.97 +/- 16.04 to 54.03 +/- 16.15 (P = 0.01). A significant correlation was observed between the Hcy and total and free testosterone levels (r = 0.44, P = 0.015 and r = 0.46, P = 0.001 respectively).
Although the decrease in Hcy levels with EE-CA therapy was statistically significant, further studies are necessary to determine the clinical benefit of this treatment.
多囊卵巢综合征（PCOS）女性具有多种心血管疾病风险因素。PCOS女性的心血管风险标志物同型半胱氨酸（Hcy）水平升高。这项前瞻性研究调查了含乙炔雌二醇 - 醋酸环丙孕酮（EE - CA）的口服避孕药对PCOS女性血清Hcy水平的影响。
共有30名PCOS女性纳入这项前瞻性研究。PCOS的诊断依据鹿特丹PCOS共识研讨会小组的标准。所有女性服用含EE/CA（35微克/2毫克）的口服避孕药3个月。在基线时自发或孕激素诱导出血的卵泡早期（第3 - 5天）以及第三个治疗周期后采集Hcy、血脂谱和激素的血清样本。
EE - CA治疗3个月后，Hcy水平从55.97±16.04显著降至54.03±16.15（P = 0.01）。观察到Hcy与总睾酮和游离睾酮水平之间存在显著相关性（分别为r = 0.44，P = 0.015和r = 0.46，P = 0.001）。
尽管EE - CA治疗使Hcy水平下降具有统计学意义，但仍需进一步研究以确定这种治疗的临床益处。
